ATAI Life Sciences NV reports results for the quarter ended in December - Earnings Summary
ATAI Life Sciences NV ATAI reported a quarterly adjusted loss of 12 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of seven analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -19 cents to -14 cents per share.
Revenue fell 52.6% to $18.00 thousand from a year ago; analysts expected $187.60 thousand.
ATAI Life Sciences NV's reported EPS for the quarter was a loss of 12 cents.
The company reported a quarterly loss of $18.29 million.
ATAI Life Sciences NV shares had risen by 27.0% this quarter.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for ATAI Life Sciences NV is $11.00
This summary was machine generated from LSEG data March 28 at 12:04 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Dec. 31 2023 | -0.16 | -0.12 | Beat |
Sep. 30 2023 | -0.20 | 0.25 | Beat |
Jun. 30 2023 | -0.21 | -0.21 | Met |
Mar. 31 2023 | -0.21 | -0.21 | Met |